SEC Filings

Form S-1
AVEXIS, INC. filed this Form S-1 on 01/15/2016
Document Outline
Entire Document (6324.4 KB)
Subdocument 1 - S-1 - S-1
Page 1 - As filed with the Securities and Exchange Commission on January 15, 2016
Page 2 - The information in this preliminary prospectus is not complete and may be changed. These securities
Page 3 - TABLE OF CONTENTS
Page 4 - PROSPECTUS SUMMARY
Page 5 - Our Product Candidate AVXS-101
Page 6 - in vivo
Page 7 - Risks Associated with Our Business
Page 8 - Implications of Being an Emerging Growth Company
Page 9 - Our Corporate Information
Page 10 - The Offering
Page 11 - N/A
Page 12 - Summary Consolidated Financial Data
Page 13 - N/A
Page 14 - RISK FACTORS
Page 15 - We have never generated revenue from product sales and may never be profitable.
Page 16 - Our limited operating history may make it difficult for you to evaluate the success of our business
Page 17 - N/A
Page 18 - Risks related to the development of our current product candidate
Page 19 - AVXS-101 is based on a novel technology, which makes it difficult to predict the time and cost of de
Page 20 - Success in preclinical studies or early clinical trials, including in our ongoing Phase 1 clinical t
Page 21 - We may find it difficult to enroll patients in our clinical trials, which could delay or prevent us
Page 22 - Because the number of subjects in our clinical trial to date is small and have all been treated at o
Page 23 - We may encounter substantial delays in our clinical trials or we may fail to demonstrate safety and
Page 24 - As we evaluate and develop manufacturing process improvements to AVXS-101, we may be required to con
Page 25 - AVXS-101 may cause undesirable side effects or have other properties that could delay or prevent its
Page 26 - As an organization, we are in the process of conducting our first Phase 1 clinical trial, and have n
Page 27 - If our competitors are able to obtain orphan drug exclusivity for products that constitute the same
Page 28 - Even if we complete the necessary clinical trials, we cannot predict when, or if, we will obtain reg
Page 29 - We face significant competition in an environment of rapid technological change and the possibility
Page 30 - Even if we obtain and maintain approval for AVXS-101 from the FDA, we may never obtain approval for
Page 31 - Risks related to our reliance on third parties
Page 32 - We may in the future enter into collaborations with third parties to develop AVXS-101. If these coll
Page 33 - We may not be successful in finding strategic collaborators for continuing development of AVXS-101 o
Page 34 - Our reliance on third parties requires us to share our trade secrets, which increases the possibilit
Page 35 - N/A
Page 36 - To the extent we rely on a third-party manufacturing facility for commercial supply, that third part
Page 37 - Risks related to the commercialization of AVXS-101
Page 38 - If we are unable to establish sales, medical affairs and marketing capabilities or enter into agreem
Page 39 - The commercial success of AVXS-101 will depend upon its degree of market acceptance by physicians, p
Page 40 - Delays in obtaining regulatory approval of our manufacturing process and facility or disruptions in
Page 41 - Failure to comply with ongoing regulatory requirements could cause us to suspend production or put i
Page 42 - The insurance coverage and reimbursement status of newly-approved products is uncertain. Failure to
Page 43 - If we obtain approval to commercialize AVXS-101 outside of the United States, in particular in the E
Page 44 - Interruptions in the supply of product or inventory loss may adversely affect our operating results
Page 45 - Risks related to our business operations
Page 46 - Our future success depends on our ability to retain key employees, consultants and advisors and to a
Page 47 - If we are unable to manage expected growth in the scale and complexity of our operations, our perfor
Page 48 - Healthcare legislative reform measures may have a material adverse effect on our business and result
Page 49 - Our relationships with customers, physicians, and third-party payors will be subject, directly or in
Page 50 - N/A
Page 51 - Product liability lawsuits against us could cause us to incur substantial liabilities and could limi
Page 52 - Third parties on which we rely and we may be adversely affected by natural disasters and our busines
Page 53 - Risks related to our intellectual property
Page 54 - If we are unable to obtain and maintain patent protection for our current product candidate, any fut
Page 55 - N/A
Page 56 - N/A
Page 57 - Our intellectual property licenses with third parties may be subject to disagreements over contract
Page 58 - We may not be successful in obtaining necessary rights to AVXS-101 through acquisitions and in-licen
Page 59 - Obtaining and maintaining our patent protection depends on compliance with various procedural, docum
Page 60 - We may not be able to protect our intellectual property rights throughout the world.
Page 61 - Issued patents covering AVXS-101 could be found invalid or unenforceable if challenged in court. We
Page 62 - Third parties may initiate legal proceedings alleging that we are infringing their intellectual prop
Page 63 - Intellectual property litigation could cause us to spend substantial resources and distract our pers
Page 64 - We may be subject to claims asserting that our employees, consultants or advisors have wrongfully us
Page 65 - N/A
Page 66 - If we do not obtain patent term extension for AVXS-101, our business may be materially harmed.
Page 67 - Intellectual property rights and regulatory exclusivity rights do not necessarily address all potent
Page 68 - Risks related to this offering and ownership of our common stock
Page 69 - After this offering, our executive officers, directors and principal stockholders will maintain the
Page 70 - If you purchase shares of common stock in this offering, you will suffer immediate dilution of your
Page 71 - An active trading market for our common stock may not develop.
Page 72 - If we engage in future acquisitions or strategic partnerships, this may increase our capital require
Page 73 - We will incur increased costs as a result of operating as a public company, and our management will
Page 74 - Provisions in our corporate charter documents and under Delaware law could make an acquisition of us
Page 75 - Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be
Page 76 - SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
Page 77 - INDUSTRY AND OTHER DATA
Page 78 - USE OF PROCEEDS
Page 79 - DIVIDEND POLICY
Page 80 - CAPITALIZATION
Page 81 - N/A
Page 82 - DILUTION
Page 83 - N/A
Page 84 - N/A
Page 85 - SELECTED CONSOLIDATED FINANCIAL DATA
Page 86 - N/A
Page 87 - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Page 88 - Licensing Agreements
Page 89 - Asklepios Biopharmaceutical, Inc.
Page 90 - General and Administrative Expense
Page 91 - Discontinued Operations
Page 92 - Equity-Based Payments to Non-Employees
Page 93 - N/A
Page 94 - Determination of the Fair Value of Stock-Based Compensation Grants
Page 95 - Common Stock Valuation Methodology
Page 96 - Tax Indemnity
Page 97 - Emerging Growth Company Status
Page 98 - Determining Whether the Host Contract in a Hybrid Financial Instrument Issued in the Form of a Share
Page 99 - Research and Development
Page 100 - Comparison of the Years Ended December 31, 2013 and 2014
Page 101 - Interest Expense
Page 102 - Cash Flows
Page 103 - Investing Activities
Page 104 - N/A
Page 105 - Contractual Obligations, Commitments and Contingencies
Page 106 - Off-Balance Sheet Arrangements
Page 107 - BUSINESS
Page 108 - in vivo
Page 109 - Our Strategy
Page 110 - Continue to invest in and develop robust and sustainable manufacturing processes and multiple supply
Page 111 - N/A
Page 112 - SMA Type 1
Page 113 - Existing Treatments for SMA
Page 114 - A recombinant AAV9 capsid shell
Page 115 - Preliminary Clinical Results
Page 116 - N/A
Page 117 - N/A
Page 118 - Preclinical Studies
Page 119 - Future SMA Type 1 Clinical Development
Page 120 - Competition
Page 121 - Licensed patents and patent applications
Page 122 - N/A
Page 123 - The Research Institute at Nationwide Children's Hospital
Page 124 - in vivo
Page 125 - Asklepios Biopharmaceutical, Inc.
Page 126 - Government Regulation and Product Approval
Page 127 - U.S. Biologic Products Development Process
Page 128 - Human Clinical Trials Under an IND
Page 129 - Phase 1.
Page 130 - Additional Regulation for Gene Therapy Clinical Trials
Page 131 - N/A
Page 132 - Orphan Drug Designation
Page 133 - Breakthrough therapy designation.
Page 134 - U.S. Patent Term Restoration and Marketing Exclusivity
Page 135 - Other Healthcare Laws and Regulations
Page 136 - Coverage and Reimbursement
Page 137 - Health Reform
Page 138 - Additional Regulation
Page 139 - Employees
Page 140 - MANAGEMENT
Page 141 - Thomas J. Dee
Page 142 - Andrew F. Knudten
Page 143 - Bong Koh
Page 144 - Classified Board of Directors
Page 145 - Role of the Board in Risk Oversight
Page 146 - Compensation Committee
Page 147 - Nominating and Corporate Governance Committee
Page 148 - Compensation Committee Interlocks and Insider Participation
Page 149 - Non-Employee Director Compensation
Page 150 - N/A
Page 151 - EXECUTIVE COMPENSATION
Page 152 - Narrative to Summary Compensation Table
Page 153 - Annual Base Salary
Page 154 - Exchange Agreement
Page 155 - Outstanding Equity Awards at December 31, 2015
Page 156 - Employment Agreements
Page 157 - Mr. Dee
Page 158 - Mr. Knudten
Page 159 - Mr. Nolan
Page 160 - Mr. Knudten
Page 161 - Reversion of Shares.
Page 162 - Tax Limitations on Incentive Stock Options.
Page 163 - Stock Appreciation Rights.
Page 164 - Other Stock Awards.
Page 165 - Corporate Transactions.
Page 166 - Stock Options
Page 167 - Amendment and Termination
Page 168 - N/A
Page 169 - CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS
Page 170 - Certain Transactions Involving Our Subsidiaries and Affiliated Entities
Page 171 - BioLife Dallas Promissory Notes Sold to Our Directors
Page 172 - Exclusive Research Collaboration Agreement with Intrexon
Page 173 - Class C Preferred Stock Financing
Page 174 - Class D Preferred Stock Financing
Page 175 - Employment Agreements
Page 176 - N/A
Page 177 - PRINCIPAL STOCKHOLDERS
Page 178 - N/A
Page 179 - N/A
Page 180 - DESCRIPTION OF CAPITAL STOCK
Page 181 - Preferred Stock
Page 182 - Registration Rights
Page 183 - Certificate of Incorporation and Bylaws to be in Effect Upon the Completion of this Offering
Page 184 - Choice of Forum
Page 185 - Transfer Agent and Registrar
Page 186 - SHARES ELIGIBLE FOR FUTURE SALE
Page 187 - Affiliates
Page 188 - Registration Rights
Page 189 - MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO NON-U.S. HOLDERS
Page 190 - Distributions on Our Common Stock
Page 191 - Information Reporting Requirements and Backup Withholding
Page 192 - N/A
Page 193 - UNDERWRITING
Page 194 - N/A
Page 195 - Selling Restrictions
Page 196 - United Kingdom
Page 197 - Japan
Page 198 - Enforcement of Legal Rights
Page 199 - LEGAL MATTERS
Page 200 - AveXis, Inc.
Page 201 - Report of Independent Registered Public Accounting Firm
Page 202 - Consolidated Balance Sheets
Page 203 - Consolidated Balance Sheets (Continued)
Page 204 - N/A
Page 205 - AveXis, Inc.
Page 206 - N/A
Page 207 - Notes to Consolidated Financial Statements
Page 208 - Notes to Consolidated Financial Statements (Continued)
Page 209 - Notes to Consolidated Financial Statements (Continued)
Page 210 - Notes to Consolidated Financial Statements (Continued)
Page 211 - Notes to Consolidated Financial Statements (Continued)
Page 212 - Notes to Consolidated Financial Statements (Continued)
Page 213 - Notes to Consolidated Financial Statements (Continued)
Page 214 - Notes to Consolidated Financial Statements (Continued)
Page 215 - Notes to Consolidated Financial Statements (Continued)
Page 216 - Notes to Consolidated Financial Statements (Continued)
Page 217 - Notes to Consolidated Financial Statements (Continued)
Page 218 - Notes to Consolidated Financial Statements (Continued)
Page 219 - Notes to Consolidated Financial Statements (Continued)
Page 220 - Notes to Consolidated Financial Statements (Continued)
Page 221 - Notes to Consolidated Financial Statements (Continued)
Page 222 - Notes to Consolidated Financial Statements (Continued)
Page 223 - Notes to Consolidated Financial Statements (Continued)
Page 224 - Notes to Consolidated Financial Statements (Continued)
Page 225 - Notes to Consolidated Financial Statements (Continued)
Page 226 - Notes to Consolidated Financial Statements (Continued)
Page 227 - Notes to Consolidated Financial Statements (Continued)
Page 228 - Notes to Consolidated Financial Statements (Continued)
Page 229 - Notes to Consolidated Financial Statements (Continued)
Page 230 - Notes to Consolidated Financial Statements (Continued)
Page 231 - Notes to Consolidated Financial Statements (Continued)
Page 232 - Notes to Consolidated Financial Statements (Continued)
Page 233 - Notes to Consolidated Financial Statements (Continued)
Page 234 - Notes to Consolidated Financial Statements (Continued)
Page 235 - Notes to Consolidated Financial Statements (Continued)
Page 236 - Notes to Consolidated Financial Statements (Continued)
Page 237 - Notes to Consolidated Financial Statements (Continued)
Page 238 - Notes to Consolidated Financial Statements (Continued)
Page 239 - Notes to Consolidated Financial Statements (Continued)
Page 240 - Notes to Consolidated Financial Statements (Continued)
Page 241 - Notes to Consolidated Financial Statements (Continued)
Page 242 - Notes to Consolidated Financial Statements (Continued)
Page 243 - Notes to Consolidated Financial Statements (Continued)
Page 244 - Notes to Consolidated Financial Statements (Continued)
Page 245 - Notes to Consolidated Financial Statements (Continued)
Page 246 - Notes to Consolidated Financial Statements (Continued)
Page 247 - Notes to Consolidated Financial Statements (Continued)
Page 248 - Notes to Consolidated Financial Statements (Continued)
Page 249 - Notes to Consolidated Financial Statements (Continued)
Page 250 - Notes to Consolidated Financial Statements (Continued)
Page 251 - Notes to Consolidated Financial Statements (Continued)
Page 252 - AveXis, Inc.
Page 253 - Part II
Page 254 - Item 15. Recent Sales of Unregistered Securities.
Page 255 - N/A
Page 256 - Stock Option Grants
Page 257 - N/A
Page 258 - SIGNATURES
Page 259 - N/A
Page 260 - Exhibit Index
Page 261 - N/A
Subdocument 2 - EX-3.1 - EX-3.1
Page 1 - Exhibit 3.1
Page 2 - RIGHTS PREFERENCES, PRIVILEGES AND RESTRICTIONS OF COMMON STOCK
Page 3 - Class B Original Issue Price
Page 4 - Voting Rights
Page 5 - Roche
Page 6 - Class B Protective Provisions
Page 7 - Conversion of Common Stock
Page 8 - Converted Shares
Page 9 - FIFTH
Page 10 - SEVENTH
Page 11 - Person
Page 12 - IN WITNESS WHEREOF, this Third Amended and Restated Certificate of Incorporation has been executed b
Subdocument 3 - EX-3.3 - EX-3.3
Page 1 - Exhibit 3.3
Page 2 - Table of Contents
Page 3 - Table of Contents
Page 4 - BYLAWS
Page 5 - Place of Meetings
Page 6 - Voting List
Page 7 - Record Date
Page 8 - Stockholder Action Without a Meeting
Page 9 - ARTICLE III DIRECTORS
Page 10 - Change in Number
Page 11 - ARTICLE IV COMMITTEES
Page 12 - ARTICLE V NOTICE
Page 13 - Chairman of the Board
Page 14 - ARTICLE VII CERTIFICATES AND STOCKHOLDERS
Page 15 - Reserves
Page 16 - Invalid Provisions
Subdocument 4 - EX-4.2 - EX-4.2
Page 1 - Exhibit 4.2
Page 2 - Delivery to Registered Holder.
Page 3 - Transfers.
Page 4 - Reservation of Stock.
Page 5 - Amendment or Waiver.
Page 6 - Entire Agreement.
Page 7 - N/A
Page 8 - EXHIBIT A
Subdocument 5 - EX-10.1 - EX-10.1
Page 1 - Exhibit 10.1
Page 2 - Damages
Page 3 - Initiating Holders
Page 4 - Restated Certificate
Page 5 - Form S-3 Demand
Page 6 - Company Registration
Page 7 - Subsection 2.2
Page 8 - provided
Page 9 - Furnish Information
Page 10 - provided
Page 11 - Reports Under Exchange Act
Page 12 - Released Securities
Page 13 - Subsection 2.1
Page 14 - Subsection 2.12(b)
Page 15 - Budget
Page 16 - Inspection
Page 17 - Janus Fund
Page 18 - Offer Notice
Page 19 - Subsection 4.1
Page 20 - Additional Compliance
Page 21 - Approving Stockholders
Page 22 - Board of Directors.
Page 23 - Class B Director
Page 24 - provided
Page 25 - unless
Page 26 - Miscellaneous
Page 27 - Schedule A
Page 28 - Amendments and Waivers
Page 29 - N/A
Page 30 - AveXis, Inc. Signature Page to Third Amended and Restated Investors Rights Agreement
Page 31 - AveXis, Inc. Signature Page to Third Amended and Restated Investors Rights Agreement
Page 32 - AveXis, Inc. Signature Page to Third Amended and Restated Investors Rights Agreement
Page 33 - AveXis, Inc. Signature Page to Third Amended and Restated Investors Rights Agreement
Page 34 - AveXis, Inc. Signature Page to Third Amended and Restated Investors Rights Agreement
Page 35 - AveXis, Inc. Signature Page to Third Amended and Restated Investors Rights Agreement
Page 36 - AveXis, Inc. Signature Page to Third Amended and Restated Investors Rights Agreement
Page 37 - AveXis, Inc. Signature Page to Third Amended and Restated Investors Rights Agreement
Page 38 - AveXis, Inc. Signature Page to Third Amended and Restated Investors Rights Agreement
Page 39 - AveXis, Inc. Signature Page to Third Amended and Restated Investors Rights Agreement
Page 40 - AveXis, Inc. Signature Page to Third Amended and Restated Investors Rights Agreement
Page 41 - AveXis, Inc. Signature Page to Third Amended and Restated Investors Rights Agreement
Page 42 - AveXis, Inc. Signature Page to Third Amended and Restated Investors Rights Agreement
Page 43 - AveXis, Inc. Signature Page to Third Amended and Restated Investors Rights Agreement
Page 44 - AveXis, Inc. Signature Page to Third Amended and Restated Investors Rights Agreement
Page 45 - AveXis, Inc. Signature Page to Third Amended and Restated Investors Rights Agreement
Page 46 - VENROCK HEALTHCARE CAPITAL PARTNERS II, L.P.
Page 47 - ROCHE FINANCE LTD
Page 48 - PBM CAPITAL INVESTMENTS, LLC
Page 49 - ADOPTION AGREEMENT
Page 50 - SCHEDULE A
Page 51 - N/A
Page 52 - N/A
Page 53 - N/A
Page 54 - SCHEDULE B
Page 55 - Deerfield Special Situations Fund, L.P. (Solely with respect to 95,588 shares of Class A Common Stoc
Subdocument 6 - EX-10.1.1 - EX-10.1.1
Page 1 - Exhibit 10.1.1
Page 2 - AGREEMENT
Page 3 - Public Company Information
Page 4 - provided
Page 5 - Joinder
Page 6 - Counsel Fees
Page 7 - N/A
Page 8 - N/A
Page 9 - N/A
Page 10 - N/A
Page 11 - N/A
Page 12 - 2(a)
Page 13 - EXHIBIT A
Subdocument 7 - EX-10.2 - EX-10.2
Page 1 - Exhibit 10.2
Page 2 - Common Stock
Page 3 - Performance Period
Page 4 - Restriction Period
Page 5 - 1.4 Eligibility.
Page 6 - II. STOCK OPTIONS AND STOCK APPRECIATION RIGHTS
Page 7 - Ten Percent Holder
Page 8 - Exercise Period and Exercisability
Page 9 - 2.4 No Repricing.
Page 10 - Stock Issuance
Page 11 - Settlement of Vested Performance Share Unit Awards
Page 12 - 5.3 Termination of Service.
Page 13 - 5.5 Director s Restricted Stock.
Page 14 - VI. GENERAL
Page 15 - Tax Date
Page 16 - 6.8 Change in Control.
Page 17 - Outstanding Common Stock
Page 18 - 6.9 No Right of Participation or Employment.
Page 19 - applicable jurisdiction. Notwithstanding any other provision of the Plan or any Agreement to the con
Subdocument 8 - EX-10.3 - EX-10.3
Page 1 - Exhibit 10.3
Page 2 - Restrictions on Transferability
Page 3 - one-fourth of the Option shall vest on the first anniversary of the Grant Date, (ii) an additional o
Page 4 - No Shareholder Rights Prior to Exercise
Page 5 - Cause
Page 6 - Retirement
Page 7 - Resolution of Disputes; Interpretation
Page 8 - Construction and Definitions
Page 9 - IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year last writ
Subdocument 9 - EX-10.4 - EX-10.4
Page 1 - Exhibit 10.4
Page 2 - N/A
Page 3 - Restrictive Legends and Stop-Transfer Orders
Page 4 - Interpretation
Subdocument 10 - EX-10.8 - EX-10.8
Page 1 - Exhibit 10.8
Page 2 - Disclosing Party
Page 3 - NDA
Page 4 - Third Party
Page 5 - Government Rights
Page 6 - Improvements
Page 7 - ARTICLE 3: CONSIDERATION
Page 8 - Third Party Royalties Stacking Provision
Page 9 - Royalty Payment Period
Page 10 - Currency, Interest
Page 11 - ARTICLE 4: DILIGENCE
Page 12 - ARTICLE 5: CONFIDENTIALITY
Page 13 - Term of Confidentiality
Page 14 - Trigger Event
Page 15 - Survival
Page 16 - Infringement Actions Against Third Parties
Page 17 - Defense of Infringement Claims
Page 18 - ARTICLE 8: WARRANTIES; INDEMNIFICATION
Page 19 - Indemnification
Page 20 - ARTICLE 9: USE OF NAME
Page 21 - Notices
Page 22 - N/A
Page 23 - No Discrimination
Page 24 - Further Assurances
Page 25 - N/A
Page 26 - Exhibit A
Page 27 - DRAFT SUBJECT TO FINAL REVIEW AND APPROVAL
Page 28 - About REGENX Biosciences
Subdocument 11 - EX-10.9 - EX-10.9
Page 1 - Exhibit 10.9
Page 2 - N/A
Page 3 - N/A
Page 4 - N/A
Page 5 - ARTICLE 2
Page 6 - ARTICLE 4
Page 7 - (a)
Page 8 - provided, however
Page 9 - ARTICLE 5
Page 10 - provided, however
Page 11 - ARTICLE 8
Page 12 - (c)
Page 13 - ARTICLE 10
Page 14 - ARTICLE 11
Page 15 - (a)
Page 16 - (b)
Page 17 - (a)
Page 18 - N/A
Page 19 - (a)
Page 20 - (b)
Page 21 - APPENDIX I
Page 22 - provided, however
Subdocument 12 - EX-10.10 - EX-10.10
Page 1 - Exhibit 10.10
Page 2 - ARTICLE 1
Page 3 - N/A
Page 4 - ARTICLE 2
Page 5 - N/A
Page 6 - N/A
Page 7 - ARTICLE 3
Page 8 - ARTICLE 4
Page 9 - N/A
Page 10 - ARTICLE 5
Page 11 - Patent Costs
Page 12 - Patent Term Extensions
Page 13 - ARTICLE 7
Page 14 - ARTICLE 8
Page 15 - N/A
Page 16 - ARTICLE 9
Page 17 - ARTICLE 11
Page 18 - Reversion of Rights
Page 19 - ARTICLE 12
Page 20 - N/A
Page 21 - EXHIBIT A
Page 22 - EXHIBIT B
Page 23 - EXHIBIT C
Page 24 - EXHIBIT D
Page 25 - EXHIBIT E
Page 26 - N/A
Page 27 - EXHIBIT F
Subdocument 13 - EX-10.11 - EX-10.11
Page 1 - Exhibit 10.11
Page 2 - N/A
Page 3 - N/A
Page 4 - N/A
Page 5 - N/A
Page 6 - N/A
Page 7 - N/A
Page 8 - N/A
Page 9 - N/A
Page 10 - N/A
Page 11 - N/A
Page 12 - N/A
Page 13 - N/A
Page 14 - N/A
Page 15 - Right Of Refusal
Page 16 - EXHIBIT A
Page 17 - EXHIBIT B
Page 18 - EXHIBIT C-1
Page 19 - EXHIBIT C-2
Subdocument 14 - EX-10.13 - EX-10.13
Page 1 - Exhibit 10.13
Page 2 - COMPENSATION
Page 3 - FACILITIES AND EXPENSES
Page 4 - Disability
Page 5 - Effect of Termination of Employment Period; Post-Termination Benefits
Page 6 - Accrued Benefits
Page 7 - Acknowledgment by the Executive
Page 8 - Termination Certification
Page 9 - Disputes or Controversies
Page 10 - Solicitation of Employees and Contractors
Page 11 - Binding Effect; Delegation of Duties Prohibited
Page 12 - LAW RULES THEREOF. VENUE FOR ANY ACTION BROUGHT HEREUNDER SHALL BE PROPER EXCLUSIVELY IN DALLAS COUN
Page 13 - CERTAIN DEFINITIONS
Page 14 - N/A
Page 15 - EXHIBIT A
Page 16 - Execution Version
Page 17 - (a)
Page 18 - (c)
Page 19 - notice to the Company, before the end of that seven (7)-day period. This agreement will not become e
Subdocument 15 - EX-10.14 - EX-10.14
Page 1 - Exhibit 10.14
Page 2 - IN WITNESS WHEREOF
Subdocument 16 - EX-10.15 - EX-10.15
Page 1 - Exhibit 10.15
Page 2 - N/A
Page 3 - Option Shares
Page 4 - Confidentiality Agreement
Page 5 - provided, however
Page 6 - (b)
Page 7 - N/A
Page 8 - IN WITNESS WHEREOF,
Subdocument 17 - EX-10.16 - EX-10.16
Page 1 - Exhibit 10.16
Page 2 - Term.
Page 3 - Other Policies Applicable to Consultant.
Page 4 - Non-Competition: Non-Solicitation
Page 5 - Non-Competition Period
Page 6 - License Agreement
Page 7 - Remedies
Page 8 - N/A
Page 9 - N/A
Page 10 - Reviewed and Acknowledged by
Page 11 - Exhibit A
Page 12 - Exhibit B
Subdocument 18 - EX-10.17 - EX-10.17
Page 1 - Exhibit 10.17
Page 2 - Notice of Intent to Purchase
Page 3 - Change in Control
Page 4 - set forth in Exhibit A attached hereto and incorporated herein by this reference, and the Company he
Page 5 - Arbitration
Page 6 - N/A
Page 7 - EXHIBIT A
Page 8 - Sophistication; Accreditation
Page 9 - provided
Page 10 - EXHIBIT B
Subdocument 19 - EX-10.18 - EX-10.18
Page 1 - Exhibit 10.18
Page 2 - NCH
Page 3 - provided, however
Page 4 - (c)
Page 5 - N/A
Page 6 - Inventions
Page 7 - N/A
Page 8 - (a)
Page 9 - (b)
Page 10 - (a)
Page 11 - COBRA Benefits
Page 12 - Cure Period
Page 13 - N/A
Page 14 - IN WITNESS WHEREOF
Subdocument 20 - EX-10.19 - EX-10.19
Page 1 - Exhibit 10.19
Page 2 - N/A
Page 3 - Option Shares
Page 4 - Confidentiality Agreement
Page 5 - provided, however,
Page 6 - (b)
Page 7 - N/A
Page 8 - IN WITNESS WHEREOF,
Subdocument 21 - EX-10.20 - EX-10.20
Page 1 - Exhibit 10.20
Page 2 - N/A
Page 3 - (a)
Page 4 - Confidentiality Agreement
Page 5 - N/A
Page 6 - (a)
Page 7 - Cure Period
Page 8 - N/A
Page 9 - IN WITNESS WHEREOF,
Subdocument 22 - EX-23.1 - EX-23.1
Page 1 - Exhibit 23.1
Print Page    E-mail Page